amblyomin-x

Amblyomin-X is a recombinant Kunitz-type protein originally derived from the salivary glands of the Amblyomma cajennense tick. It functions as a selective inhibitor of Factor Xa in the coagulation cascade and exhibits potent antitumor activity by inducing apoptosis specifically in tumor cells, while sparing normal cells. Mechanistically, Amblyomin-X disrupts tumor cell migration and metastasis by modulating Rho-GTPases and urokinase plasminogen activator receptor (uPAR) signaling, reducing matrix metalloproteinase (MMP) release, and interfering with actin cytoskeleton organization. Additionally, it can induce endoplasmic reticulum (ER) stress and modulate immune responses within the tumor microenvironment. Preclinical studies have demonstrated significant reduction in tumor mass and metastases in animal models following treatment with Amblyomin-X[1][2][4][5][6].